Design Highlights
- The TCET program expedites Medicare coverage for FDA-designated breakthrough medical devices, reducing the waiting period post-approval from 9-12 months to six months.
- Manufacturers must self-nominate a year before FDA approval to engage in the TCET process and enhance their chances of coverage.
- The program is expected to allow five devices annually for Medicare coverage, increasing from the current 3-4.
- Coverage eligibility relies on FDA breakthrough designation and alignment with Medicare benefit categories, but many devices may still not qualify.
- The TCET program aims to improve access for Medicare beneficiaries, particularly seniors, by facilitating quicker coding and coverage of innovative devices.
The Medicare TCET Program for Medical Devices is shaking things up—finally! Effective August 12, 2024, this program offers expedited national Medicare coverage for FDA-designated breakthrough devices. That’s right, folks. No more waiting in limbo for 9-12 months post-FDA approval. With TCET, Medicare beneficiaries may soon have timely access to critical technologies, assuming they meet the criteria, of course.
So, what’s the deal? The Centers for Medicare & Medicaid Services (CMS) is using existing National Coverage Determination (NCD) and Coverage with Evidence Development (CED) processes to make coverage predictable. They’re aiming to finalize NCDs within six months of FDA authorization. That’s shockingly efficient for a system that often feels stuck in quicksand.
The CMS is streamlining coverage, targeting six-month NCD finalizations post-FDA approval—now that’s efficiency in a slow-moving system!
But hold your applause; they expect only about five devices per year will make the cut. Resource constraints, they say. The irony is rich—more innovation, fewer resources. Classic!
Eligibility is no walk in the park. Devices must snag an FDA breakthrough designation and fit neatly into a Medicare benefit category. If they’re not already covered, great! But if they’re excluded by statute or regulation? Sorry, no dice.
Manufacturers need to get their self-nomination packets in about a year before FDA approval. That’s right—pre-market stage, initial meetings, and a CMS review. It’s like a game show where only the most prepared contestants get to play.
Once the device gets FDA approval, the clock starts ticking. NCDs must be finalized within six months if evidence is sufficient. This bumps up the annual NCD volume from a meager 3-4 to a potentially robust 9. Imagine that! Additionally, the TCET pathway includes an “Evidence Preview” for early feedback on evidence strength, which is a significant step forward.
But let’s not get too excited. Most breakthrough devices won’t even qualify. They’ll likely be dealt with by Medicare Administrative Contractors (MACs) instead of under the shiny new TCET umbrella.
Sure, this program aims to support patient-centered care while reducing uncertainty for manufacturers. It’s a good idea, no doubt. However, evidence development is crucial for ensuring that the devices provide real benefits to the Medicare population.
But let’s be real: limitations abound. Only five candidates annually? Exclusions for pediatric devices? Diagnostic lab tests still shuffling along via MAC determinations? It’s a clear reminder of how painstakingly slow change can be, even when it’s needed most.
In the end, the TCET program could be a game-changer for Medicare beneficiaries, especially seniors. It shortens what used to be a five-year slog to nationwide coding and coverage.
But while this program holds promise, traversing its complex landscape may feel like a high-stakes treasure hunt, minus the treasure.
